Summary Reports of Benefit-Risk Assessment

The reports contain a summary of the quality, safety and efficacy of approved new chemicals and biologics, and HSA's benefit-risk assessment for the approvals.

For the latest approved PI, please access the Online Register of Therapeutic Products.

Product name Active Ingredient(s) Product Registrant Approval date

Tukysa Film-Coated Tablets 50mg and 150mg1041 KB

*Evaluated as part of Project Orbis

 Tucatinib Nyprax Pharma Pte Ltd 2020/05/19 

Lutathera Solution for Infusion 370MBq/ml678 KB

Lutetium (177Lu) oxodotreotide Novartis (Singapore) Pte Ltd 2020/06/01


Share